Centogene Management

Management Kriterienprüfungen 2/4

Centogene's CEO ist Kim Stratton , ernannt in Dec 2021, hat eine Amtszeit von 2.67 Jahren. Die jährliche Gesamtvergütung beträgt €2.84M , bestehend aus 24.1% Gehalt und 75.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.2% der Aktien des Unternehmens, im Wert von €47.43K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.5 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

Kim Stratton

Geschäftsführender

€2.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	24.1%
Amtszeit als Geschäftsführer	2.8yrs
Eigentum des Geschäftsführers	1.2%
Durchschnittliche Amtszeit des Managements	2.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kim Stratton im Vergleich zu den Einnahmen von Centogene verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	€3m	€684k	-€36m
Sep 30 2023	n/a	n/a	-€38m
Jun 30 2023	n/a	n/a	-€40m
Mar 31 2023	n/a	n/a	-€40m
Dec 31 2022	€2m	€861k	-€39m

Vergütung im Vergleich zum Markt: KimDie Gesamtvergütung ($USD3.13M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD535.71K).

Entschädigung vs. Einkommen: KimDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Kim Stratton (62 yo)

2.8yrs

Amtszeit

€2,843,000

Vergütung

Ms. Kim Stratton serves as Chief Executive Officer at Centogene N.V. since February 18, 2022 and serves as its Member of Management Board and served as its Interim Chief Executive Officer since December 20...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kim Stratton	CEO & Member of Management Board	2.8yrs	€2.84m	1.2% € 84.2k
Jose Miguel Rios	CFO, Legal & IT and Member of Management Board	2.6yrs	€1.13m	0.48% € 33.7k
Peter Bauer	Interim MD	1.7yrs	€376.00k	0.079% € 5.5k
Andrin Oswald	Advisor	2.8yrs	€871.00k	keine Daten
Ian Rentsch	Chief Commercial Officer & GM of Pharma	1.5yrs	keine Daten	keine Daten

2.6yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: 39KDas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Eric Souêtre	Independent Member of the Supervisory Board	7.7yrs	€20.00k	keine Daten
Hubert Birner	Independent Member of the Supervisory Board	7.2yrs	€22.00k	keine Daten
Peer Schatz	Independent Chairman of the Supervisory Board	4.5yrs	€717.00k	0.26% € 18.1k
Jonathan Sheldon	Independent Member of the Supervisory Board	3.8yrs	€97.00k	keine Daten
Guido Prehn	Independent Member of the Supervisory Board	7.7yrs	€20.00k	keine Daten
Mary Sheahan	Independent Member of the Supervisory Board	1.8yrs	€239.00k	keine Daten

5.8yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 39KDie Vorstandsmitglieder gelten als erfahren (5.6 Jahre durchschnittliche Amtszeit).

Centogene Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Recent updates

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. Announces Changes to Supervisory Board

New major risk - Financial position

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings released: €1.45 loss per share (vs €2.09 loss in FY 2021)

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings released: €0.49 loss per share (vs €0.22 loss in 1Q 2021)

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Executive Officer Richard Stoffelen has left the company

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank

Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank

Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019)

Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study

New 90-day high: €10.55

New 90-day low: €9.06

Third quarter 2020 earnings released: €0.27 loss per share

Centogene N.V. to Report Q3, 2020 Results on Dec 16, 2020

Centogene Expands Express COVID-19 Antigen Testing to Frankfurt Airport

Centogene N.V. Expands Partnership with PTC Therapeutics, Inc. to Generate New Insights for Aromatic L-Amino Acid Decarboxylase Deficiency

Centogene N.V. Announces Partnership with U-Diagnostics B.V. to Provide Increased Covid-19 Testing to Communities Throughout the Netherlands

Centogene's Information Security Management System Awarded Iso/Iec 27001:2017 Accreditation

First half earnings released

New 90-day low: €8.50

Centogene Opens Walk-In COVID-1 Testing Facility At Düsseldorf Airport

Centogene N.V. to Report First Half, 2020 Results on Sep 23, 2020

New 90-day low - €9.84

New 90-day low - €10.35

Centogene N.V. has completed a Follow-on Equity Offering in the amount of $49 million.

Centogene N.V.(NasdaqGM:CNTG) dropped from Russell Microcap Value Index

Centogene N.V.(NasdaqGM:CNTG) dropped from Russell 3000 Value Index